| DC75725 |
NBQX free acid |
NBQX, also known as FG9202, is an AMPA receptor antagonist. NBQX blocks AMPA receptors in micromolar concentrations (~10–20 µM) and also blocks kainate receptors. In experiments, it is used to counter glutamate excitotoxicity. NBQX was found to have anticonvulsant activity in rodent seizure models. As the disodium salt, NBQX is soluble in water at high concentrations (at least up to 100 mM). |
|
| DC75726 |
Tranilast |
Tranilast is an analog of a tryptophan metabolite. Initially, tranilast was identified as an anti-allergic agent, and used in the treatment of inflammatory diseases, such as bronchial asthma, atypical dermatitis, allergic conjunctivitis, keloids and hypertrophic scars. Subsequently, the results showed that it could be also effective in the management of a wide range of conditions. The beneficial effects of tranilast have also been seen in a variety of disease states, such as fibrosis, proliferative disorders, cancer, cardiovascular problems, autoimmune disorders, ocular diseases, diabetes and renal diseases. |
|
| DC75727 |
CIN16645 |
CIN16645, also known as LP-01 lipid, is an ionizable lipid, IT is useful in lipid nanopparticle formulation for DNA and RNA vaccine delivery and Gene editing. CIN16645 was first reported in Novartis patent WO 2015095340A1. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).. |
|
| DC75728 |
Ansamitocin P-3' |
Ansamitocin P3' is an isomer of Ansamitocin P-3 or iso-Ansamitocin P-3 , is a natural product. Ansamitocin P-3' showed potential antineoplastic and antimitotic activity. Ansamitocin -' binds to tubulin and inhibits vinblastine-induced spiral formation. |
|
| DC75729 |
Molybdenum phosphide |
Molybdenum Phosphide has been investigated as a highly efficient electrocatalyst for various applications such as hydrogen evolution and CO2 reduction. Molybdenum phosphide exhibits high activity towards the hydrogen evolution reaction (HER) in both acid and alkaline media even in bulk form. Comparative analysis of Mo, Mo3P and MoP as catalysts for HER clearly indicates that phosphorization can potentially modify the properties of the metal and different degrees of phosphorization lead to distinct activities and stabilities. |
|
| DC75730 |
DT-2216 |
DT2216 is discontinued for commercial reasons. |
|
| DC75731 |
EPZ-025654 |
EPZ-025654 is a potent and selective arginine methyltransferase CARM1 inhibitor. |
|
| DC75732 |
RA190 HCl |
RA190 is a potent Rpn13 inhibitor and ADRM1 inhibitor, suppressing intrahepatic cholangiocarcinoma by inducing NF-kappaB-mediated cell apoptosis. |
|
| DC75733 |
2-PMDQ |
2-PMDQ is a potent selective α1 antagonist. |
|
| DC75734 |
Clobenpropit HBr |
Clobenpropit, also known as VUF 9153, is a highly potent H3 antagonist and H4 partial agonist. Clobenpropit has been shown to protect NMDA-induced neuronal necrosis in cortical neuronal cell culture from rats. Clobenpropit promises neuroprotection against LPS-induced cognitive deficits by meliorating neuroinflammation and restoring the MRCC enzymes in mice. Clobenpropit protects propofol-induced apoptosis of hippocampal neurons through PI3K/AKT pathway. |
|
| DC75735 |
Ochratoxin-A |
Ochratoxin A (OTA) is a mycotoxin produced by several fungal species including Aspergillus ochraceus, A. carbonarius, A. niger and Penicillium verrucosum. OTA causes nephrotoxicity and renal tumors in a variety of animal species; however, human health effects are less well-characterized. Various studies have linked OTA exposure with the human diseases Balkan endemic nephropathy (BEN) and chronic interstitial nephropathy (CIN), as well as other renal diseases. |
|
| DC75736 |
Selonsertib free base |
Selonsertib, also known as GS-4997, is an orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities. GS-4997 targets and binds to the catalytic kinase domain of ASK1 in an ATP-competitive manner, thereby preventing its phosphorylation and activation. GS-4997 prevents the production of inflammatory cytokines, down-regulates the expression of genes involved in fibrosis, suppresses excessive apoptosis and inhibits cellular proliferation. |
|
| DC75737 |
ML109 |
ML-109, also known as CID-25246343 and (S)-(+)-NCGC00161870, is a potent and full thyroid stimulating hormone receptor (TSHR) agonist. ML109 is the first selective and orally available small-molecule TSHR agonist, and the probe will be a useful pharmacological tool to study TSHR biology in thyroidal and extrathyroidal tissues |
|
| DC75738 |
Ibrutinib Interm 0441 |
Ibrutinib Interm 0441 is a piperidine derivative with an amine protecting group. It may be used in the preparation of biologically active compounds such as antagonists of the human P2X7 receptor and selective irreversible inhibitors for brutons tyrosine kinase. |
|
| DC75739 |
Ipatasertib dihydrochloride |
Ipatasertib, also known as GDC-0068, is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor GDC-0068 binds to and inhibits the activity of Akt in a non-ATP-competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. |
|
| DC75740 |
Elamipretide |
Elamipretide, also known as MTP 131, is a mitochondria-targeted peptide antioxidant. Elamipretide decreases inflammation and protect against a variety of neurological illnesses. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. Elamipretide Promotes Mitophagosome Formation and Prevents Its Reduction Induced by Nutrient Excess in INS1 β-cells. |
|
| DC75741 |
J147 |
J147 is a potent neuroprotective and neurotrophic compound. J147 protects against neurotoxicity in cortical neurons in vitro (EC50 = 25 - 200 nM). J147. J147 reverses cognitive impairment in aged Alzheimer's disease mice. J147 is an exciting new compound that is extremely potent, safe in animal studies and orally active. J147 is a potential AD therapeutic due to its ability to provide immediate cognition benefits, and it also has the potential to halt and perhaps reverse disease progression in symptomatic animals as demonstrated in these studies. |
|
| DC75742 |
Bexagliflozin |
Bexagliflozin, also known as EGT1442, is a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats. The IC(50) values for EGT1442 against human SGLT1 and SGLT2 are 5.6μM and 2nM, respectively. In normal rats and dogs a saturable urinary glucose excretion was produced with an ED(50) of 0.38 and 0.09mg/kg, respectively. EGT1442 showed favorable properties both in vitro and in vivo and could be beneficial to the management of type 2 diabetic patients. |
|
| DC75743 |
Isavuconazonium sulfate |
Isavuconazole (BAL4815; trade name Cresemba) is a triazole antifungal drug. Its prodrug, isavuconazonium sulfate (BAL8557), was granted approval by the U.S. Food and Drug Administration (FDA) on March 6, 2015. Isavuconazole has been approved for treatment of invasive aspergillosis and invasive mucormycosis in adults ages 18 years and older. Both infections are caused by mold and fungi common to the environment, and occur in individuals who are immunosuppressed or have other complicating conditions, such as diabetes or lung disease. |
|
| DC75744 |
Vesatolimod |
Vesatolimod, also known as GS-9620, is a potent and oral agonist of Toll-like receptor-7 developed for finite treatment of chronic hepatitis B viral (HBV) infection, with the goal of inducing a liver-targeted antiviral effect without inducing the adverse effects associated with current systemic interferon-α (IFN-α) therapies. GS-9620 demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. GS-9620 can induce a sustained antiviral response in the woodchuck model of CHB. |
|
| DC75745 |
Mitoxantrone free base |
Mitoxantrone is an anthraquinone that intercalates in DNA and inhibits topoisomerase II (IC50 = 5.3 μM), thus inhibiting cell proliferation. It also inhibits HIV-1 integrase (IC50 = 3.8 μM). Mitoxantrone is exported from cells in an ATP- and glutathione-dependent manner by multidrug resistance protein-1.4 Formulations containing mitoxantrone have been used in the treatment of cancer and multiple sclerosis. |
|
| DC75746 |
Epirubicin free base |
Epirubicin is an anthracycline drug used for chemotherapy. It can be used in combination with other medications to treat breast cancer in patients who have had surgery to remove the tumor. Similarly to other anthracyclines, epirubicin acts by intercalating DNA strands. Intercalation results in complex formation which inhibits DNA and RNA synthesis. It also triggers DNA cleavage by topoisomerase II, resulting in mechanisms that lead to cell death. Binding to cell membranes and plasma proteins may be involved in the compound's cytotoxic effects. Epirubicin also generates free radicals that cause cell and DNA damage. |
|
| DC75747 |
Siponimod |
Siponimod, also known as BAF-312, is a a potent and orally selective S1P Receptor Modulator with EC50 value of 0.39nM for S1P1 receptors and 0.98nM for S1P5 receptors, respectively. Development of sphingosine-1-phosphate receptor 1 (S1P1) modulators to dampen inflammation and its sequelae is becoming increasingly promising for treating medical conditions characterized by significant immunopathology. |
|
| DC75748 |
Ivarmacitinib free base |
Ivarmacitinib, also known as SHR0302, is a novel potent JAK inhibitor which blocks JAK/STAT3 signaling, suppresses proliferation, migration and collagen production, and induces the apoptosis of hepatic stellate cells. SHR0302 may attenuate the severity of AA rats, partially through reducing Th17 function and total B cell proportion by inhibiting JAK1-STAT3 phosphorylation. |
|
| DC75749 |
Acalabrutinib (ACP-196) |
Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival. |
|
| DC75750 |
WIC1 |
WIC1 is a novel potent Wnt inhibitor, promoting airway basal stem cell homeostasis, acting to repress phosphorylation of β-cateninY489 and Tp63 expression. |
|
| DC75751 |
Osimertinib mesylate |
Osimertinib, also known as mereletinib and AZD-9291, is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines. Osimertinib was approved on Nov. 2015. |
|
| DC75752 |
ICI-118551 HCl |
ICI-118551, also known as ICI-118,551 and ICI 111581, is a selective beta-2 (β2) adrenergic receptor antagonist. ICI-118551 binds to the β2 subtype with at least 100 times greater affinity than β1 or β3, the two other known subtypes of the beta adrenoceptor. The compound was developed by Imperial Chemical Industries, which was acquired by AkzoNobel in 2008. ICI-118,551 has no known therapeutic use in humans although it has been used widely in research to understand the action of the β2 adrenergic receptor, as few other specific antagonists for this receptor are known. |
|
| DC75753 |
Enasidenib (AG-221) |
Enasidenib, also known as AG-221 and CC-90007, is a potent and selective IDH2 inhibitor with potential anticancer activity (IDH2 = Isocitrate dehydrogenase 2). The mutations of IDH2 present in certain cancer cells result in a new ability of the enzyme to catalyze the NAPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG). The production of 2HG is believed to contribute to the formation and progression of cancer . The inhibition of mutant IDH2 and its neoactivity is therefore a potential therapeutic treatment for cancer. |
|
| DC75754 |
DPY-9309 |
DPY-9309, CAS#511529-30-9, is a useful intermediate for chemical synthesis of a number of biologically important molecules, including porphyrins, N-confused porphyrin, bile pigments, photosensitizers, anticancer drugs. |
|
